Since its introduction in 2000, the European Congress of Rheumatology has become the primary platform for exchanging scientific and clinical information in Europe. It is a highly recognised event which facilitates interaction between expert medical doctors and scientists, people with arthritis/rheumatism, health professionals and representatives of the healthcare industry each year.

EULAR, the European Alliance of Associations for Rheumatology is proud to present to you the Satellite Symposia and Consult the Expert sessions organised by our industry partners as well as a comprehensive list of exhibitors showcasing at EULAR 2023.
INDUSTRY PROGRAMME

PROGRAMME OVERVIEW  6
WEDNESDAY  9
THURSDAY  21
FRIDAY  41

EXHIBITORS

INDUSTRY PARTNERS  54
WHERE YOU CAN FIND OUR
INDUSTRY PARTNERS AT THE CONGRESS  55
INDUSTRY PARTNERS DESCRIPTION  57
Join us at our Satellite Symposia!

AbbVie is inviting you to join Prof. Kimme Hyrich, Prof. Laure Gossec and Prof. Filip Van den Bosch, as they discuss, together with other clinical experts in the field, the importance of tailoring individualized treatment decisions, based on benefit:risk assessment and disease manifestations, across rheumatic conditions.

**Tailor-made Care**
Why Benefit: Risk Assessment Should Drive Individualized Treatment Decisions

*WEDNESDAY, 31 MAY 2023*
18:30 – 19:45 CEST
South Hall, Session Room 2

PROFS. KIMME HYRICH, SUZAN ATTAR, MAYA BUCH, AND DR. CHRISTINA CHARLES-SCHOEMAN

**Tailoring PsA**
Therapy to Fit the Patient
Are Emerging Therapies Part of Your Collection?

*THURSDAY, 1 JUNE 2023*
08:15 – 09:30 CEST
Room Brown 3

PROFS. LAURE GOSSC, MARIA ANTONETTA D’AGOSTINO, AND LARS ERIK KRISTENSEN

**SpA on the Runway**
A Front Row Seat for a Closer Look at the Latest Trends

*THURSDAY, 1 JUNE 2023*
17:30 – 18:45 CEST
South Hall, Session Room 2

PROF. FILIP VAN DEN BOSCH, DR. VICTORIA NAVARRO-COMPÁN, AND DR. WILLIAM TILLET

These sessions will address the latest evidence and key considerations when selecting therapy for the patients you see daily in your practice.
### Satellite Symposium

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker and Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>15:45–16:15</strong></td>
<td><strong>ABBVIE</strong>&lt;br&gt;Monitoring and management of lung fibrosis in patients with autoimmune diseases</td>
</tr>
<tr>
<td><strong>15:45–16:15</strong></td>
<td><strong>GSK</strong>&lt;br&gt;Raising ambitions with clinical remission in EGPA</td>
</tr>
<tr>
<td><strong>15:45–16:15</strong></td>
<td><strong>CSL VIFOR</strong>&lt;br&gt;What the Rheumatologist needs to know about the kidney in ANCA-associated vasculitis</td>
</tr>
<tr>
<td><strong>18:30–19:45</strong></td>
<td><strong>ABBVIE</strong>&lt;br&gt;Tailor-made Care – Why Benefit: risk Assessment Should Drive Individualized Treatment Decisions</td>
</tr>
<tr>
<td><strong>18:30–19:45</strong></td>
<td><strong>MEDSCAPE EDUCATION GLOBAL (SUPPORTED BY UCB)</strong>&lt;br&gt;Raising the Bar: Optimizing Outcomes in Spondyloarthritis</td>
</tr>
<tr>
<td><strong>18:30–19:45</strong></td>
<td><strong>JANSSEN</strong>&lt;br&gt;IL-23 in PsA: connecting the domains of skin, gut, and joint</td>
</tr>
<tr>
<td><strong>18:30–19:45</strong></td>
<td><strong>GSK</strong>&lt;br&gt;Is there a “window of opportunity” in SLE?</td>
</tr>
<tr>
<td><strong>18:30–19:45</strong></td>
<td><strong>ASTRAZENECA</strong>&lt;br&gt;Writing a new chapter in long-term lupus care</td>
</tr>
<tr>
<td><strong>18:30–19:45</strong></td>
<td><strong>SOBI</strong>&lt;br&gt;The many faces of inflammation: which cytokine should I target, when, and why?</td>
</tr>
</tbody>
</table>
## Thursday 1 June 2023

### 08:15–09:30

**ABBVIE**
Tailoring PsA Therapy to Fit the Patient – Are Emerging Therapies Part of Your Collection?

**ELI LILLY**
Finding the right treatment for the right patient: what similarities and key differences among RA, PsA and axSpA determine treatment decisions

**NOVARTIS**
Getting to the root of PsA and axSpA

**GSK**
Shielding against shingles: how do we optimize care for our patients?

**ASTRAZENECA**
Anifrolumab in SLE – perspectives from the real world

**EUSA PHARMA**
Unexplained lymphadenopathies: how a multidisciplinary approach can lead to a better diagnosis

### 09:45–10:15

**JANSSEN**
Partners in managing PsA: collaboration with Gastroenterology

**GSK**
Is there a “window of opportunity” in SLE?

**NOVARTIS**
Advancing AOSD care: expert opinion on the latest guidelines

**GSK**
Can Disease Modification Help Us Tackle Organ Damage and Excess Mortality in SLE?

### 15:00–15:30

**UCB**
Facing the Challenges of the Impact of Gender in SpA

**NOVARTIS**
Advancing AOSD care: expert opinion on the latest guidelines

**GSK**
Can Disease Modification Help Us Tackle Organ Damage and Excess Mortality in SLE?

### 17:30–18:45

**ABBVIE**
Spa on the Runway – A Front Row Seat for a Closer Look at the Latest Trends

**PFIZER**
Connections between the gut, joint and spine: evidence and experience with JAK inhibitors

**UCB**
The time is NOW! Aiming for higher treatment targets in PsA and axSpA

**JANSSEN**
Moving closer to optimal pain management and timing intervention in PsA

**BOEHRINGER INGELHEIM**
Optimising the management of patients with autoimmune disease-related ILDs through interdisciplinary discussions

**GALAPAGOS**
JAK to reality: seeking clarity in RA

**CELLTRION HEALTHCARE**
Infliximab IV to SC: Mainstay Therapy in Rheumatology

**CSL VIFOR**
Targeting unmet needs in ANCA-associated vasculitis – can we do better?
<table>
<thead>
<tr>
<th>Time</th>
<th>Company</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15–09:30</td>
<td>Pfizer</td>
<td>Unpacking the data: who are the appropriate patients with RA for a JAK inhibitor?</td>
</tr>
<tr>
<td>09:45–10:15</td>
<td>Janssen</td>
<td>What would you do? An interactive discussion on PsA scenarios</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>AstraZeneca</td>
<td>Treat to Target: how biologics can help?</td>
</tr>
<tr>
<td>17:30–18:45</td>
<td>CSF</td>
<td>The &quot;Case&quot; for JAK Inhibitors- How JAK inhibition can be optimised in the treatment of varying RA patient populations, using case studies.</td>
</tr>
<tr>
<td>09:45–10:15</td>
<td>Galapagos</td>
<td>Burning questions: the practical use of JAK inhibitors in RA</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>CSL Vifor</td>
<td>Shared decision making in ANCA-associated vasculitis</td>
</tr>
<tr>
<td>09:45–10:15</td>
<td>Medac</td>
<td>Improving first-line therapy of RA patients with optimized methotrexate</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>Gsk</td>
<td>How can we Tackle the Early Drivers of Organ Damage and Excess Mortality in SLE?</td>
</tr>
<tr>
<td>09:45–10:15</td>
<td>Roche</td>
<td>Inspired to move mountains: optimising care in systemic lupus</td>
</tr>
<tr>
<td>15:00–15:30</td>
<td>Otuka</td>
<td>Lupus Nephritis: can we talk about a change of perspective today?</td>
</tr>
<tr>
<td>09:45–10:15</td>
<td>Kyverna</td>
<td>CAR T Cell Therapy in B Cell Driven Autoimmune Diseases</td>
</tr>
</tbody>
</table>

**Satellite Symposium**

**Consult the Expert**
INDUSTRY PROGRAMME ON WEDNESDAY 31 MAY 2023

Status as of 23 May 2023
BOEHRINGER INGELHEIM

MONITORING AND MANAGEMENT OF LUNG FIBROSIS IN PATIENTS WITH AUTOIMMUNE DISEASES

LEARNING OBJECTIVE(S):

- There remain many uncertainties in how ILD associated with autoimmune diseases should be monitored and managed, but a multidisciplinary approach, involving collaboration between (at minimum) a pulmonologist and a rheumatologist, is recommended.
- The objective of this meeting is to enable rheumatologists to discuss key questions related to the detection, monitoring and management of autoimmune disease-related ILDs with a pulmonologist with substantial expertise in this field.

Dr. MARLIES WIJSENBEEK

15:45 Monitoring and management of lung fibrosis in patients with autoimmune diseases (M. Wijsenbeek)
RAISING AMBITIONS WITH CLINICAL REMISSION IN EGPA

LEARNING OBJECTIVE(S):
- To emphasise the need for timely biologic initiation for patients with EGPA in order to help achieve Clinical Remission.
- To drive Clinical Remission to reduce the adverse effects of long-term OCS use on patients’ physical and mental wellbeing.
- To review patient needs and ensure clinicians have the necessary tools to practically implement lasting benefit for patients with EGPA.

MERRITT ETZEL
Prof. Dr. BERNHARD HELLMICH
Dr. PhD ROBERTO PADOAN

15:45 Introduction (M. Etzel)
15:46 Clinical Remission: a new future of lasting change in EGPA:
What is clinical remission and what does it mean for the patient.
How is EULAR defining clinical remission?
Brief overview of evidence on remission within EGPA landscape.
Patient case study - treatment journey and management overview to highlight importance of Clinical Remission. (B. Hellmich, R. Padoan)
16:01 Consult the Expert Q+Á (B. Hellmich, R. Padoan)
16:13 Summary and close (M. Etzel)
15:45–16:15  CTE 2

CONSULT THE EXPERT

CSL VIFOR

WHAT THE RHEUMATOLOGIST NEEDS TO KNOW ABOUT THE KIDNEY IN ANCA-ASSOCIATED VASCULITIS

LEARNING OBJECTIVE(S):
| To discuss the importance of how, when and why to monitor renal function throughout the disease course of ANCA-associated vasculitis.

Prof. Dr. CRISTINA PONTE

15:45  What the Rheumatologist needs to know about the kidney in ANCA-associated vasculitis (C. Ponte)

---

Raising the Bar
Optimizing Outcomes in Spondylarthritis

WEDNESDAY, 31 MAY 2023  |  18:30 – 19:45 CET

MICO CONVENTION CENTER, PIAZZALE CARLO MAGNO, 1
MILANO, ITALY  |  ROOM: BROWN 1 & 2

IN-PERSON EVENT

MODERATOR
Helena Marzo-Ortega, LMS, MRCP, PhD

PANELISTS
William Tillett, MBChB, PhD, FRCP
Filip Van den Bosch, MD, PhD

EULAR European Congress of Rheumatology 2023 Industry Symposia

Supported by an independent educational grant from UCB Pharma, Inc.
TAILOR-MADE CARE – WHY BENEFIT: RISK ASSESSMENT SHOULD DRIVE INDIVIDUALIZED TREATMENT DECISIONS

LEARNING OBJECTIVE(S):

| Determine the baseline risk of a patient in clinical practice based on their underlying rheumatic disease, individual risk factors and existing comorbidities. |
| Develop strategies to optimize the benefit: risk balance of prescribed advanced therapies for individual patients. |
| Implement a shared decision-making process for individualized treatment decisions. |

Prof. KIMME HYRICH
Dr. CHRISTINA CHARLES-SCHOEMAN
Prof. SUZAN ATTAR
Prof. DR. MAYA H BUCH

18:30 Introduction (K. Hyrich, S. Attar, M. H. Buch, C. Charles-Schoeman)
18:31 Tailor-made care – Enhancing the benefit: risk discussion (K. Hyrich)
18:40 The many factors that affect the benefit: risk equation (C. Charles-Schoeman)
18:50 Calculating risk in the clinic – tools that can simplify these assessments (S. Attar)
19:00 Adjusting risk - A collaborative approach to improving disease control and lowering risk (M. H. Buch, K. Hyrich)
19:25 Translating it to the individual patient in your clinic when considering a JAKi (K. Hyrich, S. Attar, M. H. Buch, C. Charles-Schoeman)
19:40 Question and Answer (K. Hyrich)
MEDSCAPE EDUCATION GLOBAL (SUPPORTED BY UCB)

RAISING THE BAR: OPTIMIZING OUTCOMES IN SPONDYLOARTHRITIS

LEARNING OBJECTIVE(S):
- Have increased knowledge regarding the: Monitoring disease activity using objective measures in PsA and axSpA; Appropriate treatment targets for patients with PsA and axSpA; Evidence on implementing treatment goals.
- Demonstrate greater confidence in their ability to: Achieve suppression of disease activity in clinical practice.

Dr. HELENA MARZO-ORTEGA
Dr. WILLIAM TILLETT
Prof. FILIP VAN DEN BOSCH

18:30 Welcome and Introductions (H. Marzo-Ortega)
18:35 Long-term Disease Control in PsA and axSpA (H. Marzo-Ortega)
18:45 Monitoring Disease Activity and Selecting Appropriate Treatment Targets in PsA (W. Tillet)
19:00 Monitoring Disease Activity and Selecting Appropriate Treatment Targets in axSpA (F. v. d. Bosch)
19:35 Q&A (H. Marzo-Ortega, W. Tillet, F. v. d. Bosch)
TREAT EARLY TODAY FOR HER TOMORROW†1-4

CIMZIA® (certolizumab pegol), with 15 years of experience,5 provides long-term efficacy and safety data in axSpA, RA, PsA and PsO.4-8 As a unique Fc-free TNFi, CIMZIA® offers a differentiated solution FOR HER4,9

Visit stand M1&2 to find out more

CIMZIA® SmPC can be found here

CIMZIA® in adult patients is indicated for the treatment of: moderate to severe active RA, severe active axSpA, active PsA and moderate to severe PsO.

axSpA, axial spondyloarthritis; Fc, fragment crystallisable; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; TNFi, tumour necrosis factor inhibitor.

* CIMZIA® should only be used during pregnancy if clinically needed.


Depositato presso AIFA in data 04/04/2023 IT-P-CZ-axSpA-2300024

CIMZIA® 200 mg soluzione iniettabile in penna preriempita, 2 penne preriempite + 2 salviettine imbevute di alcool - AIC n. 039539059 - Prezzo al Pubblico €1,519,29 - Classe H* CIMZIA® 200 mg soluzione iniettabile in siringa preriempita, 2 siringhe preriempite + 2 salviettine imbevute di alcool - AIC n. 039539010 - Prezzo al Pubblico €1,519,29 - Classe H* Da vendersi dietro presentazione di ricetta medica limitativa su prescrizione di centri ospedalieri o di specialisti: reumatologo, internista, dermatologo (RRL). *L’indicazione terapeutica “trattamento dell’artrite reumatode grave, attiva e progressiva in adulti non precedentemente trattati con metotrexato o con altri DMARDs” non è dispensabile a carico del SSN. D.Lgs. 219/2006, Art. 119, comma 3

Date of preparation: April 2023
© UCB Biopharma SRL, 2023. All rights reserved.
JANSSEN

IL-23 IN PSA: CONNECTING THE DOMAINS OF SKIN, GUT, AND JOINT

LEARNING OBJECTIVE(S):

| Examine the pathophysiological mechanisms driving PsA disease progression and inflammation. |
| Examine the role of IL-23 as a key cytokine driver of inflammatory diseases. |
| Understand the involvement of skin and gut domains in PsA and considerations for patient management. |
| Integrate patient and disease characteristics, including clinical features and comorbidities, into disease management. |

Prof. DENNIS MCGONAGLE
KILIAN EYERICH
Dr. MATTHIEU ALLEZ

18:30 Welcome and Introduction (D. McGonagle, K. Eyerich)
18:35 Stand up and look around: moving beyond the joint (short presentation with audience interactivity) (D. McGonagle)
18:45 Panel discussion and Q&A session (M. Allez, D. McGonagle, K. Eyerich)
18:55 Evolving senses: why is the skin relevant for rheumatologists? (K. Eyerich)
19:05 Panel discussion and Q&A session (M. Allez, D. McGonagle, K. Eyerich)
19:15 Changing from the inside: why is the gut important for rheumatologists? (M. Allez)
19:25 Panel discussion and Q&A session (M. Allez, D. McGonagle, K. Eyerich)
19:40 Final thoughts and close (D. McGonagle, K. Eyerich)
IS THERE A “WINDOW OF OPPORTUNITY” IN SLE?

LEARNING OBJECTIVE(S):
Experts in SLE will evaluate current treatment challenges and discuss the potential for a targeted treatment approach to improve long-term patient outcomes. This will help physicians to be aligned on short-term and long-term treatment goals to control active disease and/or flares, while at the same time, reducing the risk of organ damage progression.

Prof. Dr. ANDREAS SCHWARTING
MD, PhD JOSE A. GOMEZ-PUERTA
Dr. FRANCESCA ROMANA SPINELLI

18:30 Welcome and Introduction (A. Schwarting)
18:40 How can we do better in the treatment of SLE? (J. A. Gomez-Puerta)
18:50 Discussion 1: What are the current approaches to glucocorticoid dosage? (A. Schwarting, F. R. Spinelli, J. A. Gomez-Puerta)
19:00 How can a targeted therapy slow down progression of organ damage in the clinic? (F. R. Spinelli)
19:10 Discussion 2: Why do we need to establish a “window of opportunity” in SLE? (A. Schwarting, F. R. Spinelli, J. A. Gomez-Puerta)
19:30 Q&A session (A. Schwarting, F. R. Spinelli, J. A. Gomez-Puerta)
19:40 Closing remarks (A. Schwarting)
ASTRAZENECA

WRITING A NEW CHAPTER IN LONG-TERM LUPUS CARE

**LEARNING OBJECTIVE(S):**

| Describe the chronic burden that lupus places on patients’ lives, and consider treatment strategies to minimise GC use, maximise HRQoL and achieve comprehensive disease control. |
| Assess the long-term safety and efficacy of targeted therapies for SLE and what this means for patients. |
| Explain how refocusing clinical practice towards the long-term management of SLE can improve patient outcomes. |

Prof. MARCELINE GOVONI  
Dr. IRENE BULTINK  
Prof. GEORGE BERTSIAS  
Prof. ERIC F. MORAND

18:30 Welcome and Introduction (M. Govoni)  
18:35 Living with lupus – understanding the patient experience of chronic disease (I. Bultink)  
18:45 Rewriting lupus outcomes through a treat-to-target approach (G. Bertsias)  
18:55 Q&A and discussion (M. Govoni, E. F. Morand, G. Bertsias, I. Bultink)  
19:05 Achieving long-term disease control – are we entering a new chapter of care? (E. F. Morand)  
19:20 Transforming clinical practice – turning the page on the management of SLE (M. Govoni)  
19:30 Q&A, discussion and close (M. Govoni, E. F. Morand, G. Bertsias, I. Bultink)
SOBI

THE MANY FACES OF INFLAMMATION: WHICH CYTOKINE SHOULD I TARGET, WHEN, AND WHY?

**LEARNING OBJECTIVE(S):**

- To understand the pathogenesis of autoinflammatory and hyperinflammatory conditions, the role of cytokines in autoinflammatory and hyperinflammatory conditions, the current and emerging evidence for targeted therapies in autoinflammatory and hyperinflammatory conditions, and how to apply the concept of ‘window of opportunity’ in autoinflammatory and hyperinflammatory conditions.

Prof. Dr. CARINE WOUTERS  
Prof. Dr. FABRIZIO DE BENEDETTI  
Dr. SEBASTIAN VASTERT

18:30 Chair’s welcome and introduction (C. Wouters)  
18:35 Audience poll (C. Wouters)  
18:40 Autoinflammation: pathways and targets (C. Wouters)  
18:55 Hyperinflammation: pathways and targets (F. D. Benedetti)  
19:10 Applying the ‘window of opportunity’ (S. Vastert)  
19:25 Audience poll with Q&A (C. Wouters, F. D. Benedetti, S. Vastert)  
19:40 Summary and close (C. Wouters)
ACTIVELY RECRUITING
CLINICAL TRIALS

Phase 3: Two Studies with Deucravacitinib in Rheumatology

Trial number 1: NCT04908202, EudraCT Number: 2020-005097-10,
WHO/UTN: U1111-1259-9443, IM011-054
Trial number 2: NCT04908189, EudraCT Number: 2020-005099-36,
WHO/UTN: U1111-1259-9466, IM011-055

Phase 3: Two Studies with Deucravacitinib in Rheumatology

Trial number 1: NCT05617677, EudraCT Number: 2022-500699-76, IM011-246
Trial number 2: NCT05620407, EudraCT Number: 2022-500700-22, IM011-247

Phase 2: A Study with Deucravacitinib in Rheumatology and Dermatology

Trial number: NCT04857034, EudraCT Number: 2020-000071-21,
WHO/UTN: U1111-1246-1726, IM011-132

Phase 2: A Study with Afimetoran in Rheumatology

Trial number: NCT04895696, EudraCT Number: 2019-004021-25,
WHO/UTN: U1111-1241-6528, IM026-024

For more information about these clinical trials:

Email: Clinical.Trials@bms.com

For more information, visit bmsstudyconnect.com

©2023 Bristol-Myers Squibb Company
IMM-TT-2300028 03/23
INDUSTRY PROGRAMME ON THURSDAY 1 JUNE 2023

Status as of 23 May 2023
ABBVIE

TAILORING PSA THERAPY TO FIT THE PATIENT – ARE EMERGING THERAPIES PART OF YOUR COLLECTION?

LEARNING OBJECTIVE(S):

| ‘Spotlight’ the multifaceted manifestations of PsA and recommended therapies for each domain. |
| ‘Cut’ through and ‘critique’ the efficacy data of emerging treatments, such as IL-23i, for PsA across the domains. |
| Appraise the safety data of emerging treatments for PsA to appropriately ‘tailor’ treatment selection. |

Prof. LAURE GOSSEC
MD, PhD LARS ERIK KRISTENSEN
Prof. Dr. MARIA-ANTONIETTA D’AGOSTINO

08:15–09:30 BROWN 3

08:15–09:30 SATELLITE SYMPOSIUM

08:15 Introduction Welcome Video (L. Gossec, L. E. Kristensen, M. A. D’Agostino)
08:16 Introduction (L. Gossec)
08:20 Patterned Perspectives: Exploring the multifaceted manifestations of the PsA patient (L. Gossec)
08:40 Fashion Faceoff: Examining the efficacy data of emerging treatments across the PsA domains (L. E. Kristensen)
09:05 Tailoring Trends: Reviewing the safety data of emerging treatments for PsA to optimize treatment selection (M. A. D’Agostino)
09:20 Key learnings and panel discussion (L. Gossec, L. E. Kristensen, M. A. D’Agostino)
FINDING THE RIGHT TREATMENT FOR THE RIGHT PATIENT: WHAT SIMILARITIES AND KEY DIFFERENCES AMONG RA, PSA AND AXSPA DETERMINE TREATMENT DECISIONS

LEARNING OBJECTIVE(S):
| Discuss the key differentiators between 3 rheumatology conditions. 
| Discuss the importance of finding the right treatment for the right patient in each disease. 
| Increase confidence among the rheumatologist community in using baricitinib and ixekizumab in their daily practice.

Prof. ROBERTO CAPORALI
Prof. RIK LORIES
MD, PhD KUNIHIRO YAMAOKA
Dr. RAJ SENGUPTA

08:15 Finding the right treatment for the right patient: what similarities and key differences among RA, PsA and axSpA determine treatment decisions (R. Caporali, R. Lories, K. Yamaoka, R. Sengupta)
# GETTING TO THE ROOT OF PSA AND AXSPA

**LEARNING OBJECTIVE(S):**
- Discuss treatment options for PsA, according to updated GRAPPA treatment recommendations, available data and patient perspectives.
- Update on treatment goals and recommendations in axSpA to highlight the importance of evidence-based treatment decisions.
- Overview of the impact, burden, and treatment of radiographic progression in axSpA.

Prof. Dr. **ENNIO LUBRANO**  
Prof. **PETER NASH**  
Dr. **SOFIA RAMIRO**  
Prof. Dr. **LIANNE S. GENSLER**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Welcome (E. Lubrano)</td>
</tr>
<tr>
<td>08:20</td>
<td>New stems: Making a difference for patients with PsA (P. Nash)</td>
</tr>
<tr>
<td>08:40</td>
<td>Branching out: Recent advances in the management of axSpA (S. Ramiro)</td>
</tr>
<tr>
<td>08:55</td>
<td>Digging deeper: New evidence in the management of radiographic progression in axSpA (L. S. Gensler)</td>
</tr>
<tr>
<td>09:15</td>
<td>Turning over a new leaf for patients: Panel discussion with Q&amp;A (L. S. Gensler, P. Nash, E. Lubrano, S. Ramiro)</td>
</tr>
<tr>
<td>09:29</td>
<td>Closing remarks (E. Lubrano)</td>
</tr>
</tbody>
</table>
Is there a “window of opportunity” in SLE?

**Symposium:** 31st May, 18:30–19:45 CEST  
Amber room 3 & 4, Level 2

**Consult the Expert:** 1st June, 09:45–10:15 CEST  
Hall 3, Level 0, CTE 1

The event was duly communicated to the competent AIFA office, within the terms and in the manner established by art. 124, co.1 of Legislative Decree 215/06 and subsequent implementing provisions, and complies with the requirements established by the current Farmindustria Code of Conduct.

An industry symposium sponsored and organised by GSK. GSK products will be discussed.  
Prescribing Information for all GSK products discussed will be available at the event and the GSK booth.

PM-GBL-BEL-ADVT-230018. Date of preparation: March 2023
LEARNING OBJECTIVE(S):
- Reinforce the burden of herpes zoster (HZ) in patients with autoimmune inflammatory rheumatic diseases (AIIRDs).
- Consider the importance of HZ prevention with the recombinant zoster vaccine in the 18+ year old increased-risk patient population.
- Provide expert insights into the optimal integration of HZ vaccination into the treatment journey for patients with AIIRDs.

Prof. ANDREA DORIA
Prof. LEONARD CALABRESE
Dr. KEVIN WINTHROP

08:15 Welcome and introduction (A. Doria)
08:20 Where are we now? Herpes zoster vaccination in rheumatology (L. Calabrese)
08:35 What have we learned? Recombinant zoster vaccine in practice (K. Winthrop)
08:50 Open Q&A (A. Doria, K. Winthrop, L. Calabrese)
09:00 What would you do? Integrating herpes zoster vaccination into the treatment journey (A. Doria, K. Winthrop, L. Calabrese)
ASTRAZENECA

ANIFROLUMAB IN SLE – PERSPECTIVES FROM THE REAL WORLD

LEARNING OBJECTIVE(S):
- Understand the clinical data supporting the long-term use of anifrolumab in SLE.
- Highlight real-world challenges associated with managing SLE, including the optimisation of glucocorticoid use.
- Consider which patients may be appropriate for treatment with anifrolumab, with the aim of improving patient outcomes and health-related quality of life.

Dr. CHIARA TANI
Prof. Dr. RONALD VAN VOLLENHOVEN
PANDLETON WICHERSHAM
Prof. Dr. PETER PEICHL
Dr. PETER KORSTEN
Prof. MERAV LIDAR

08:15 Welcome and introductions (C. Tani, R. van Vollenhoven)
08:35 Real-world experiences with anifrolumab – hear from international experts (C. Tani, R. van Vollenhoven, P. Wichersham, P. Peichl, P. Korsten, M. Lidar)
09:15 Panel discussion and Q&A (C. Tani, R. van Vollenhoven, P. Wichersham, P. Peichl, P. Korsten, M. Lidar)
EUSA PHARMA

UNEXPLAINED LYMPHADENOPATHIES: HOW A MULTIDISCIPLINARY APPROACH CAN LEAD TO A BETTER DIAGNOSIS

LEARNING OBJECTIVE(S):
Increase iMCD disease awareness among rheumatologists, focusing on the impact of the disease (also from a patient perspective) and the typical clinical presentation that a rheumatologist can see; educate on differential diagnosis of iMCD vs other rheumatological diseases.

Prof. Dr. CARLO SELMI
Dr. PUJA MEHTA
Dr. DAVID FAJGENBAUM

08:15 Introduction of the symposium objectives (C. Selmi)
08:20 From unexplained lymphadenopathies to diagnosing Idiopathic Multicentric Castleman Disease (iMCD) (C. Selmi)
08:35 Challenges in differential diagnosis in iMCD (P. Mehta)
08:55 iMCD Disease Management: The Patient and Expert perspective (D. Fajgenbaum)
09:15 Live Q&A (C. Selmi, P. Mehta, D. Fajgenbaum)
JANSSEN

PARTNERS IN MANAGING PSA: COLLABORATION WITH GASTROENTEROLOGY

LEARNING OBJECTIVE(S):
- Integrate patient and disease characteristics, including clinical features, comorbidities and concomitant diseases, and quality of life into PsA management.
- Evaluate the benefits of cross-specialty collaboration in the management of PsA, patient comorbidities, and concomitant diseases.

Dr. RICHARD SMITH
ALESSANDRO ARMUZZI

09:45  Welcome and introduction (R. Smith)
09:48  A rheumatologist’s approach to PsA (R. Smith)
09:56  A gastroenterologist’s approach to IBD (A. Armuzzi)
10:04  Working together for our patients (R. Smith, A. Armuzzi)
10:12  Final thoughts and close (A. Armuzzi)

GSK

IS THERE A “WINDOW OF OPPORTUNITY” IN SLE?

LEARNING OBJECTIVE(S):
- Evaluate current treatment challenges and discuss the potential for a targeted treatment approach to reduce organ damage progression and improve both short- and long-term patient outcomes.

Prof. Dr. ANDREAS SCHWARTING
Dr. FRANCESCA ROMANA SPINELLI
MD, PhD JOSE A. GOMEZ PUERTA

09:45  Discussion topics: How can we better address current treatment challenges in SLE? How do targeted therapies benefit patients with SLE? When is the “window of opportunity” in SLE? (A. Schwarting, F. R. Spinelli, J. A. Gomez-Puerta)
UCB

FACING THE CHALLENGES OF THE IMPACT OF GENDER IN SPA

LEARNING OBJECTIVE(S):
- To understand the impact of gender in SpA, including unmet needs and challenges for female patients.

Dr. ELENA NIKIPHOROU  
Prof. Dr. ENNIO LUBRANO

15:00 Welcome and Introduction (E. Nikiphorou, E. Lubrano)  
15:02 Impact of Gender in axSpA: Understanding the unmet needs and challenges for female axSpA patients. Clinical evidence in axSpA (E. Nikiphorou)  
15:12 Impact of Gender in PsA: Understanding the unmet needs and challenges for female PsA patients. Clinical evidence in PsA (E. Lubrano)  
15:22 Question and Answer Discussion (E. Nikiphorou, E. Lubrano)

NOVARTIS

ADVANCING AOSD CARE: EXPERT OPINION ON THE LATEST GUIDELINES

LEARNING OBJECTIVE(S):
- Raise awareness of the current local AOSD management guidelines.  
- Share expert opinion on the diagnostic criteria, disease activity measures and treatment recommendations in patients with AOSD.  
- Highlight the role IL-1 inhibitors in achieving sustained disease remission and tapering the use of corticosteroids in patients with AOSD.

Prof. EUGEN FEIST  
Prof. Dr. LUCA CANTARINI

15:00 Welcome and introductions (E. Feist)  
15:02 AOSD management guidelines: expert opinion (E. Feist, L. Cantarini)  
15:22 Q&A session and close (E. Feist, L. Cantarini)
GSK

CAN DISEASE MODIFICATION HELP US TACKLE ORGAN DAMAGE AND EXCESS MORTALITY IN SLE?

LEARNING OBJECTIVE(S):
To discuss the role of disease modification in addressing long-term impacts of SLE. Including:
· Would establishing disease modification as a treatment target help improve long-term outcomes in SLE?
· How do the components of disease modification relate to the drivers of excess mortality in SLE?

Prof. MARCELLO GOVONI
Prof. BIMBA FRANZISKA HOYER
Prof. RICARD CERVERA

15:00 Setting the scene (M. Govoni)
15:05 Discussion and audience Q&A (M. Govoni, B. F. Hoyer, R. Cervera)
15:29 Closing and thanks (M. Govoni)
ABBVIE

SPA ON THE RUNWAY - A FRONT ROW SEAT FOR A CLOSER LOOK AT THE LATEST TRENDS

LEARNING OBJECTIVE(S):

| Discuss key issues associated with the assessment and diagnosis of axSpA and PsA. |
| Apply current evidence to determine the optimal treatment based on disease burden for specific patients with axSpA or PsA. |
| Modify therapy to allow the patient to reach their treatment goals. |
| Adjust the management plan for patients with difficult-to-treat characteristics. |

Prof. FILIP VAN DEN BOSCH
Dr. VICTORIA NAVARRO-COMPAN
Dr. WILLIAM TILLETT

17:30–18:45 SOUTH HALL, SESSION ROOM 2 SATELLITE SYMPOSIUM

17:30 Introduction (F. van den Bosch, V. Navarro-Compan, W. Tillett)
17:31 Optimizing SpA across the Lifespan – From the First Visit to Advanced Care (F. van den Bosch)
17:35 Starting the SpA runway – Setting your patients on the right path from diagnosis (V. Navarro-Compan, W. Tillett)
17:55 SpA Runway Success – Setting up your patients to reach their goals (V. Navarro-Compan, W. Tillett)
18:25 Ensuring every person has runway success – Managing patients with difficult-to-treat characteristics (V. Navarro-Compan, W. Tillett)
18:40 Summary and Q&A Session (F. van den Bosch, V. Navarro-Compan, W. Tillett)
Join GSK Medical Affairs at EULAR 2023

**SCIENTIFIC CONSULT THE EXPERT SESSION**

Can Disease Modification Help Us Tackle Organ Damage and Excess Mortality in SLE?
Thursday 1st June
15:00 – 15:30 CEST
(CTE 1)
Access is first-come, first-served

**SCIENTIFIC SYMPOSIUM**

How Can We Tackle the Early Drivers of Organ Damage and Excess Mortality in SLE?
Friday 2nd June
08:15 – 09:30 CEST
(South Hall, Space 4)

**SPEAKERS**

Professor Marcello Govoni (Chair), Professor Bimba Hoyer & Professor Ricard Cervera

Join us at our medical booth at C1 and C2

For healthcare professionals only

This material is not subject to the provisions and submission required by AIFA
Industry sponsored scientific sessions organised by GSK at EULAR 2023
©2023 GSK group of companies or its licensor
NX-GBL-LPU-ADVT-230001 March 2023
CONNECTIONS BETWEEN THE GUT, JOINT AND SPINE: EVIDENCE AND EXPERIENCE WITH JAK INHIBITORS

OVERVIEW:
Join a panel of multidisciplinary experts as they explore the clinical management of patients with spondyloarthritis (SpA) and inflammatory bowel disease (IBD). The speakers will touch upon the epidemiological, clinical, and pathophysiological basis for the intersection of these conditions and their associated disease management. They will then discuss experiences and successes in applying a combined rheumatology and gastroenterology approach to clinical care of patients with SpA and IBD. The panel will also examine the evidence for use of Janus kinase (JAK) inhibitors in patients with ankylosing spondylitis (AS), psoriatic arthritis (PsA), and ulcerative colitis (UC), and how these data can help to identify appropriate patients for JAK inhibitor treatment.

LEARNING OBJECTIVE(S):
- Explore the pathophysiological basis for the intersection of SpA and IBD, manifestations of disease and impact on the patient.
- Describe disease management and treatment selection considerations while applying a rheumatology/gastroenterology multidisciplinary approach.
- Discuss the benefits, risks and experiences with JAK inhibitors in AS, PsA and UC; strengthen understanding of which patients may be appropriate candidates for treatment with JAK inhibitors.

Dr. SOFIA RAMIRO
Prof. Dr. LIANNE S. GENSLER
SILVIO DANESE

17:30 Welcome and introduction (S. Ramiro)
17:35 Exploring the important relationship between SpA and IBD (S. Ramiro)
17:50 Navigating clinical management of patients with SpA and IBD, considering an interdisciplinary approach (L. S. Gensler, S. Danese, S. Ramiro)
18:05 Assessing the benefits/risks of JAK inhibitors and appropriate patient selection from rheumatology and gastroenterology perspectives (L. S. Gensler, S. Danese, S. Ramiro)
18:40 Summary and close (S. Ramiro)
THE TIME IS NOW! AIMING FOR HIGHER TREATMENT TARGETS IN PSA AND AXSPA

LEARNING OBJECTIVE(S):
- Recognise the patient benefit of achieving higher treatment targets and utilizing objective measures of inflammation in PsA and axSpA.
- Examine treatment strategies including the recommendations of current guidelines around disease control.
- Identify how HCPs can elevate the standard of care and how aiming for higher treatment targets could be adopted in clinical practice.

Prof. Dr. FRANCESCO CICCIA
MD, PhD LARS ERIK KRISTENSEN
PD Dr. med. FABIAN PROFT
Prof. Dr. DENIS PODDUBNYY

17:30 Welcome and introductions from the Chair (F. Ciccia)
17:32 Raising the bar: Should we aim higher for our patients with PsA? (L. E. Kristensen)
17:47 Panel discussion: In which patients should we aim for high treatment targets? (F. Ciccia, L. E. Kristensen, D. Poddubnyy, F. Proft)
17:57 Raising the bar: What is the optimal treatment target for patients with axSpA? (F. Proft)
18:12 Panel discussion: Should treatment decisions be based solely on clinical response driven by PROs? (F. Ciccia, L. E. Kristensen, D. Poddubnyy, F. Proft)
18:22 Why is aiming for higher targets now more feasible than ever? (D. Poddubnyy)
18:37 Closing remarks (F. Ciccia)
LEARNING OBJECTIVE(S):
| Evaluate the clinical implications of the heterogeneity and the pathophysiology of PsA. |
| Understand the importance of early diagnosis and treatment for the disease course and for long-term remission. |
| Differentiate therapies for PsA based on mechanisms of action, efficacy and safety data, and impact on patient-reported outcomes. |
| Integrate patient and disease characteristics, including clinical features, comorbidities, and quality of life, into disease management. |

Prof. Dr. CARLO SELMI
Dr. HELENA MARZO-ORTEGA
Prof. Dr. GEORG SCHETT
Prof. LAURE GOSSEC
PD Dr. med. FRANK BEHRENES

17:30 Welcome and introduction (C. Selmi)
17:35 Presenting the patient situation: part 1 (C. Selmi)
17:40 Tick-tock: considerations for early intervention (H. Maryo-Ortega)
17:45 Tick-tock: considerations for late intervention (G. Schett)
17:50 Conclusion and key points of debate 1 (L. Gossec, G. Schett, F. Behrens, C. Selmi, H. Maryo-Ortega)
18:05 Presenting the patient situation: part 2 (G. Schett)
18:10 Doctor, my joints hurt, why? Considerations for pain management (L. Gossec)
18:15 Doctor, my joints hurt, why? Considerations for inflammation management (F. Behrens)
18:20 Conclusion and key points of debate 2 (L. Gossec, G. Schett, F. Behrens, C. Selmi, H. Maryo-Ortega)
18:40 Final thoughts and close (G. Schett, C. Selmi)
BOEHRINGER INGELHEIM

OPTIMISING THE MANAGEMENT OF PATIENTS WITH AUTOIMMUNE DISEASE-RELATED ILDS THROUGH INTERDISCIPLINARY DISCUSSIONS

LEARNING OBJECTIVE(S):
- Highlight the potential for interstitial lung disease (ILD) associated with systemic sclerosis (SSc) or rheumatoid arthritis (RA) to become fibrosing and progressive and the importance of prompt detection, monitoring and management of SSc-ILD and RA-ILD.
- Emphasise the importance of interdisciplinary discussion in optimising the monitoring and management of patients with autoimmune disease-related ILDs.
- Examine the evidence supporting treatment options for SSc-ILD and RA-ILD.

Prof. YANNICK ALLANORE
Prof. Dr. HELMUT PROSCH
Dr. MARLIES WIJSENBEEK
Prof. VANESSA SMITH
MD, PhD ANNA-MARIA HOFFMANN-VOLD

17:30 Introduction (Y. Allanore)
17:35 Challenges in the management of a patient with SSc-ILD (Y. Allanore, H. Prosch, V. Smith, M. Wijsenbeek)
18:10 Challenges in the management of a patient with RA-ILD (Y. Allanore, H. Prosch, M. Wijsenbeek, A.M Hoffmann-Vold)
GALAPAGOS

JAK TO REALITY: SEEKING CLARITY IN RA

LEARNING OBJECTIVE(S):
- Review the key considerations when selecting a treatment for a patient with RA.
- Explore the efficacy and safety of JAK inhibitors in RA, including filgotinib clinical trial and real-world data.
- In the context of recent developments in the RA treatment landscape, discuss the practical use of JAK inhibitors in the treatment of patients with RA.

Dr. ENNIO GIULIO FAVALLI
Prof. Dr. ANJA STRANGFELD
Dr. JAMES GALLOWAY

17:30 Welcome and introduction (E. G. Favalli)
17:35 Mapping the course for JAK inhibitors: treatment choices in RA (E. G. Favalli)
17:50 In search of answers: real-world data on JAK inhibitors in RA (A. Strangfeld)
18:05 Following the trail: a practical view on JAK inhibitors in RA (J. Galloway)
18:20 Q&A with all faculty (E. G. Favalli, A. Strangfeld, J. Galloway)
18:40 Summary and meeting close (E. G. Favalli)
INFLIXIMAB IV TO SC: MAINSTAY THERAPY IN RHEUMATOLOGY

LEARNING OBJECTIVE(S):

- To revisit the path of the first monoclonal antibody biosimilar from its approval to real world evidence of efficacy, safety, and patient access.
- To review up-to-date data on treatment optimisation of infliximab therapy for RA patients, addressing its underlying mechanisms in relation to pharmacokinetics.
- To explore the possibilities of achieving treatment goals with subcutaneous infliximab in patients with ankylosing spondylitis.

Prof. ROBERTO GIACOMELLI  
Prof. Dr. BRUNO FAUTREL  
Dr. RAJ SENGUPTA

17:30 Introduction (R. Giacomelli)  
17:35 A Decade of Monoclonal Antibody Biosimilars (B. Fautrel)  
17:50 Treatment Optimisation with IFX in Patients with Rheumatoid Arthritis (R. Giacomelli)  
18:05 Treatment of Patients with Ankylosing Spondylitis with Infliximab SC (R. Sengupta)  
18:20 Q&A and Discussion (R. Giacomelli, B. Fautrel, R. Sengupta)
TARGETING UNMET NEEDS IN ANCA-ASSOCIATED VASCULITIS – CAN WE DO BETTER?

LEARNING OBJECTIVE(S):
| To explore the burden of disease and quality of life impairment for patients with AAV. |
| To explore the balancing act between benefit and harms of treatment choices in the context of a systemic disease affecting multiple organs. |

Prof. CARLO SALVARANI  
Prof. Dr. BERNHARD HELLMICH  
Dr. SARA MONTI  
Prof. DAVID JAYNE

17:30 Welcome and introductions (C. Salvarani)  
17:35 ANCA-associated vasculitis: Unmet needs from different angles (B. Hellmich, D. Jayne)  
17:55 What’s new in ANCA-associated vasculitis? (S. Monti)  
18:15 Treating patients in the real world – from data to clinical practice (B. Hellmich, D. Jayne)  
18:30 Q&A (C. Salvarani)  
18:44 Concluding remarks (C. Salvarani)
INDUSTRY PROGRAMME ON FRIDAY 2 JUNE 2023

Status as of 23 May 2023
UNPACKING THE DATA: WHO ARE THE APPROPRIATE PATIENTS WITH RA FOR A JAK INHIBITOR?

OVERVIEW:
Join an esteemed international faculty as they delve into the data on the benefit and risk profile of Janus kinase (JAK) inhibitors in rheumatoid arthritis (RA) patient subpopulations. After taking a tour of the efficacy data for each JAK inhibitor in the overall RA population, the faculty will focus on efficacy data in patients with different baseline demographics and disease characteristics. They will then discuss safety data across different patient subgroups, including those who are identified as higher risk and lower risk for adverse events while on a JAK inhibitor. Throughout the session, the expert faculty will reflect on the clinical significance of the data.

LEARNING OBJECTIVE(S):
| Explore data on efficacy of JAK inhibitors, including tofacitinib, in patients with RA with different demographics. |
| Discuss safety data for JAK inhibitors, including tofacitinib, that can help to identify higher-risk and lower-risk patients with RA for JAK inhibitor treatment. |

Prof. ROBERTO CAPORALI
Dr. EDUARDO MYSLER
Dr. GRACE C. WRIGHT
Prof. Dr. MAYA H. BUCH

08:15 Welcome and introduction (R. Caporali)
08:20 Exploring the efficacy of JAK inhibitors for patients with RA (E. Mysler, G. C. Wright)
08:50 How can data help identify patients with RA at higher risk versus lower risk of adverse events while on a JAK inhibitor? (M. H. Buch)
09:20 Q&A and close (M. H. Buch, E. Mysler, R. Caporali, G. C. Wright)
THE GREAT DEBATE: FORCE OF HABIT VS. INNOVATIVE APPROACH IN THE MANAGEMENT OF INFLAMMATORY RHEUMATIC DISEASES

LEARNING OBJECTIVE(S):
- Discuss the learnings, challenges and evolution in the management of inflammatory rheumatic diseases over the years, focusing on RA, PsA and axSpA.
- Debate a more “innovative” versus the more “established” management approach.

Prof. Dr. CARLO SELMI
PD Dr. med. FABIAN PROFT
Dr. FRANCESCA ROMANA SPINELLI
Prof. Dr. MART VAN DE LAAR
Dr. HELENA MARZO-ORTEGA

MEDAC

IMPROVING FIRST-LINE THERAPY OF RA PATIENTS WITH OPTIMIZED METHOTREXATE

LEARNING OBJECTIVE(S):

- Learn more on the management of patients with rheumatoid arthritis (RA) by using first-line medication methotrexate (MTX) optimally, for example, in a presentation on the results of a clinical study with Japanese patients. Also, find out how an optimized early therapy with MTX may help to prevent difficult-to-treat RA. Added to that, recent trends of methotrexate therapy in RA will be covered, e.g., circumventing a possible effect of the microbiome and the recently altered view on MTX and RA-interstitial lung disease.

Prof. TORSTEN WITTE
Prof. YOSHIYA TANAKA
Prof. ANDREA RUBBERT-ROTH
MD, PhD ALESSANDRO GIOLLO

08:15–09:30 AMBER 3+4 SATELLITE SYMPOSIUM

08:15 Welcome and introduction (T. Witte)
08:20 Clinical benefit of methotrexate and the subcutaneous route for RA therapy (T. Witte)
08:35 Efficacy and tolerability of subcutaneous methotrexate in Japanese patients with RA (Y. Tanaka)
08:50 Recent developments of methotrexate therapy in RA (A. Rubbert-Roth)
09:05 Optimized methotrexate therapy in early RA may prevent difficult-to-treat RA (A. Giollo)
09:20 Discussion and Farewell (T. Witte, Y. Tanaka, A. Rubbert-Roth, A. Giollo)
GSK

HOW CAN WE TACKLE THE EARLY DRIVERS OF ORGAN DAMAGE AND EXCESS MORTALITY IN SLE?

LEARNING OBJECTIVE(S):
- Highlight the long-term impacts of SLE on patients’ lives, in particular organ damage and excess mortality.
- To explore the drivers of these long-term impacts: disease activity and treatment toxicity (in the case of organ damage), infections and renal/cardiovascular disease (in the case of excess mortality).
- To consider how these drivers can be addressed when making management decisions.

Prof. MARCELLO GOVONI
Prof. RICARD CERVERA
Prof. BIMBA FRANZISKA HOYER

08:15 Introduction: The long-term impact of SLE on patients (M. Govoni)
08:30 Understanding the drivers of organ damage and excess mortality in SLE (B. F. Hoyer)
08:50 Management strategies to limit the long-term impacts of SLE (R. Cervera)
09:10 Audience Q&A (M. Govoni, B. F. Hoyer, R. Cervera)
INSPIRED TO MOVE MOUNTAINS: OPTIMISING CARE IN SYSTEMIC LUPUS

LEARNING OBJECTIVE(S):
| To understand the challenges associated with patient care in systemic lupus and raise awareness of different therapies being developed for future treatment of the disease.

Prof. ERIC F. MORAND
Prof. LAURENT ARNAUD
Prof. MATTEO PIGA
Prof. MARTIN ARINGER

08:15–09:30 AMBER 1+2

08:15 Welcome and Introduction (E. F. Morand, L. Arnaud)
08:20 Surveying the mountain: what are the main challenges in systemic lupus today? (M. Piga)
08:35 A matter of perspective: how do treat-to-target goals differ for patients and HCPs? (E. F. Morand)
08:50 Navigating the route: how can we optimize patient pathways in SLE? (L. Arnaud)
09:05 Glimpsing the horizon: what does the future treatment of systemic lupus look like? (M. Aringer)
09:20 Q&A and Close (E. F. Morand, L. Arnaud)
Writing a New Chapter in Long-Term Lupus Care

Wednesday 31 May 2023 | 18:30–19:45 CEST

Join Prof Marcello Govoni (Chair), Dr Irene Bultink, Prof George Bertsias and Prof Eric Morand as they consider the chronic burden of lupus and explore the role that targeted treatment strategies can play in transforming patients’ lives in the long term.

Welcome and introduction
Living with lupus – understanding the patient experience of chronic disease
Rewriting lupus outcomes through a treat-to-target approach
Achieving long-term disease control – are we entering a new chapter of care?
Transforming clinical practice – turning the page on the management of SLE

Anifrolumab in SLE
Perspectives from the real world

Thursday 1 June 2023; 08:15–09:30 CEST

Welcome and introductions (Co-chairs)
- Doctor Chiara Tani
- Professor Ronald van Vollenhoven

Real-world experiences with anifrolumab – hear from international experts
- Doctor Pendleton Wickersham
- Doctor Peter Peichl
- Professor Merav Lidar
- Doctor Peter Korsten

Panel discussion and Q&A

Join the expert panel as they reflect on their clinical experience and consider published data to explore four key questions with the aim of elevating outcomes for patients with SLE:

What should our patients expect from SLE treatment?
How important is early and sustained disease control in SLE?
Why should we look at reducing patient exposure to GCs?
What are the most important outcomes for our patients?

This symposium is organised and funded by AstraZeneca. For healthcare professionals only. Prescribing information will be available at the meeting.
LEARNING OBJECTIVE(S):
| Lupus nephritis pathophysiology. 
| Guidelines recommendations for the current treatment of LN and the unmet needs. 
| New therapeutic approaches in the treatment of LN. 
| How LN patient journey could evolve based on the new treatment landscape. 

Prof. ANDREA DORIA
Prof. JÜRGEN FLOEGE
MD, PhD DRA MARÍA GALINDO-IZQUIERDO

08:15 Introduction (A. Doria)
08:20 The kidney and lupus nephritis in a nutshell (J. Floege)
08:35 Current treatment guidelines: where do we stand? (D. M. Galindo-Izquierdo)
08:45 New options for patients with lupus nephritis (J. Floege)
09:00 How different therapeutic strategies could change patient journey in lupus nephritis (D. M. Galindo-Izquierdo)
09:15 Roundtable discussion and live Q&A (A. Doria, J. Floege, D. M. Galindo-Izquierdo)
LEARNING OBJECTIVE(S):
- Understand the role of B cells in autoimmune diseases and the rationale for pursuing deeper B cell depletion through CAR T cell therapy.
- Review the clinical data in the use of anti-CD19 CAR T cell therapy in SLE and other autoimmune diseases.
- Understand how the lessons learned from the experience of CD19 CAR T therapy in oncology informs its development for autoimmune diseases.

Prof. PETER A. MERKEL
PhD PETER MAAG
Prof. Dr. GEORG SCHETT
PhD, MD DOMINIC BORIE
Prof. Dr. DAVID JAYNE
Dr. CARLOTTA CACCIATURE

08:15 Welcome and Introduction (P. Maag)
08:20 Role of B cells in Autoimmune Diseases (P. A. Merkel)
08:35 Anti-CD19 CAR T Therapy in SLE and other Autoimmune Diseases (G. Schett)
08:55 Applying Learnings From CellTherapy in Oncology toDevelopment in Autoimmune Diseases (D. Borie)
09:10 Panel discussion (P. A. Merkel, P. Maag, G. Schett, D. Borie, D. Jayne, C. Cacciatore)
WHAT WOULD YOU DO? AN INTERACTIVE DISCUSSION ON PSA SCENARIOS

LEARNING OBJECTIVE(S):
- Integrate patient and disease characteristics into clinical decision-making.
- Understand the importance of PsA disease domains and early diagnosis and treatment for the disease course and for long-term remission.

Dr. ALEN ZABOTTI
PD Dr. med VALENTIN SCHÄFER

09:45 Welcome (A. Zabotti)
09:46 Do we need to treat differently? (A. Zabotti)
09:50 Ready, set, go! A clinical discussion on PsA (V. Schäfer)
10:00 Is it a marathon or a sprint? PsA management in practice (A. Zabotti)
10:10 Conclusions and close (V. Schäfer)
CSL VIFOR

SHARED DECISION MAKING IN ANCA-ASSOCIATED VASCULITIS

**LEARNING OBJECTIVE(S):**
- To discuss the principles of shared decision making and how to implement it in the vasculitis clinic.

**Dr. JOANNA ROBSON**

09:45  Shared decision making in ANCA-associated vasculitis (J. Robson)

ASTRAZENECA

TREAT TO TARGET: HOW BIOLOGICS CAN HELP?

**LEARNING OBJECTIVE(S):**
- Recognize the urgency of treating patients with SLE to decrease organ damage and achieve remission.
- Understand the importance of achieving comprehensive disease control to optimise patient outcomes and quality of life.
- Evaluate biologics as a line of treatment in the SLE population from a treat to target perspective.

**Dr. FABRIZIO CONTI**
**Prof. MATTEO PIGA**
**Prof. LUCA IACCARINO**

15:00  Welcome and introductions (F. Conti)
15:05  Roundtable about Treat to Target and biologic role in a new era of SLE management (M. Piga, L. Iaccarino)
15:25  Summary and close (F. Conti)
THE “CASE” FOR JAK INHIBITORS- HOW JAK INHIBITION CAN BE OPTIMISED IN THE TREATMENT OF VARYING RA PATIENT POPULATIONS, USING CASE STUDIES

**LEARNING OBJECTIVE(S):**
- Elucidate the current understanding of JAK inhibition, its safety, and how it fits within the treatment paradigm for RA.
- Describe ways to optimise JAK inhibition, including target populations and treatment strategies.
- Discuss at what line of treatment JAK inhibition would best be used in, considering the latest updates to labelling.

Dr. ELENA NIKIPHOROU  
Prof. LORENZO DAGNA  
Prof. PETER NASH

17:30  Background Introduction (E. Nikiphorou)  
17:40  Clinical Considerations in Initiating JAK Inhibitors in RA (P. Nash)  
18:05  Clinical consideration in managing RA patients on JAK inhibitors (L. Dagna)  
18:30  Discussion (E. Nikiphorou, P. Nash, L. Dagna)  
18:40  Summary and Close (E. Nikiphorou)
CREATING A MASTERPIECE IN RA MANAGEMENT: HOW WILL NEW BIOSIMILARS SHIFT THE FOCUS TO ALTERNATIVE TREATMENT STRATEGIES FOR YOUR PATIENTS?

LEARNING OBJECTIVE(S):

To educate rheumatologists on topics of interest and ultimately improve the diagnosis and care of RA patients using alternative treatment options.

Prof. PETER C. TAYLOR
PD Dr. med. VALENTIN SCHÄFER
Dr. ANDRAS ILLES

17:30 - 18:30

17:30 Introduction (P. C. Taylor)
17:35 Sketching the Key Landmarks: Ultrasound imaging and diagnostics in Rheumatoid Arthritis (V. Schäfer)
17:51 Bringing Colour to the Canvas: Advanced Therapies and most recent evidence base recommendations in RA (P. C. Taylor)
18:07 Adding Fine Brushstrokes: New PhIII data from the APTURA 1 Trial on the tocilizumab biosimilar (A. Illes)
18:23 Conclusion (P. C. Taylor)
18:30 Questions & Answers (P. C. Taylor, V. Schäfer, A. Illes)
## CORPORATE MEMBERS

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBVIE</td>
<td>57</td>
</tr>
<tr>
<td>PFIZER</td>
<td>58</td>
</tr>
<tr>
<td>UCB</td>
<td>59</td>
</tr>
<tr>
<td>JANSSEN</td>
<td>60</td>
</tr>
<tr>
<td>ELI LILLY</td>
<td>61</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>62</td>
</tr>
<tr>
<td>BOEHRINGER INGELHEIM</td>
<td>63</td>
</tr>
<tr>
<td>MEDAC</td>
<td>64</td>
</tr>
<tr>
<td>BRISTOL MYERS SQUIBB</td>
<td>64</td>
</tr>
<tr>
<td>GALAPAGOS</td>
<td>65</td>
</tr>
<tr>
<td>AMGEN</td>
<td>66</td>
</tr>
<tr>
<td>GSK</td>
<td>66</td>
</tr>
<tr>
<td>ASTRAZENECA</td>
<td>67</td>
</tr>
<tr>
<td>ROCHE</td>
<td>68</td>
</tr>
<tr>
<td>FRESENIUS KABI</td>
<td>69</td>
</tr>
<tr>
<td>IBSA INSTITUT BIOCHIMIQUE</td>
<td>70</td>
</tr>
<tr>
<td>CELLTRION HEALTHCARE</td>
<td>70</td>
</tr>
<tr>
<td>CSL VIFOR</td>
<td>71</td>
</tr>
<tr>
<td>MERCK</td>
<td>71</td>
</tr>
<tr>
<td>OTSUKA</td>
<td>72</td>
</tr>
<tr>
<td>BMJ</td>
<td>74</td>
</tr>
<tr>
<td>CANON MEDICAL SYSTEMS EUROPE</td>
<td>75</td>
</tr>
<tr>
<td>CLARIUS MOBILE HEALTH</td>
<td>76</td>
</tr>
<tr>
<td>CLINICAL AND EXPERIMENTAL RHEUMATOLOGY</td>
<td>77</td>
</tr>
<tr>
<td>CSF</td>
<td>77</td>
</tr>
<tr>
<td>DS MEDICA</td>
<td>78</td>
</tr>
<tr>
<td>ESAOTE</td>
<td>78</td>
</tr>
<tr>
<td>EUSA PHARMA</td>
<td>79</td>
</tr>
<tr>
<td>EXPANSCIENCE</td>
<td>79</td>
</tr>
<tr>
<td>FIDIA FARMACEUTICI</td>
<td>80</td>
</tr>
<tr>
<td>GE HEALTHCARE</td>
<td>80</td>
</tr>
<tr>
<td>HORIZON THERAPEUTICS</td>
<td>81</td>
</tr>
<tr>
<td>IDORSIA</td>
<td>81</td>
</tr>
<tr>
<td>KYVERNA</td>
<td>82</td>
</tr>
<tr>
<td>MEDSCAPE</td>
<td>82</td>
</tr>
<tr>
<td>NORDIC PHARMA</td>
<td>83</td>
</tr>
<tr>
<td>PERIMED</td>
<td>84</td>
</tr>
<tr>
<td>PHILIPS</td>
<td>84</td>
</tr>
<tr>
<td>PRIOVANT</td>
<td>84</td>
</tr>
<tr>
<td>ROPCA</td>
<td>85</td>
</tr>
<tr>
<td>SOBI</td>
<td>86</td>
</tr>
<tr>
<td>THE JOURNAL OF RHEUMATOLOGY</td>
<td>87</td>
</tr>
<tr>
<td>WISEPRESS</td>
<td>87</td>
</tr>
<tr>
<td>XIRALITE</td>
<td>88</td>
</tr>
</tbody>
</table>

## CORPORATE NON-MEMBERS

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCORD HEALTHCARE</td>
<td>73</td>
</tr>
<tr>
<td>ADAMO SRL</td>
<td>73</td>
</tr>
<tr>
<td>APTISSEN</td>
<td>74</td>
</tr>
</tbody>
</table>
YOU CAN FIND OUR INDUSTRY PARTNERS AT ...

THE EXHIBITION AREA  HALL 3, LEVEL 0

<table>
<thead>
<tr>
<th>Industry Partner</th>
<th>Hall/Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBVIE</td>
<td>J/K</td>
</tr>
<tr>
<td>ACCORD HEALTHCARE</td>
<td>B1.1</td>
</tr>
<tr>
<td>ADAMO S.R.L.</td>
<td>N12</td>
</tr>
<tr>
<td>AMGEN</td>
<td>D3/E3</td>
</tr>
<tr>
<td>APTISSEN</td>
<td>M3</td>
</tr>
<tr>
<td>ASTRazeneca</td>
<td>F1/G1</td>
</tr>
<tr>
<td>BMJ</td>
<td>N5</td>
</tr>
<tr>
<td>BOEHRINGER INGELHEIM</td>
<td>F2/F3+G2/G3</td>
</tr>
<tr>
<td>BRISTOL MYERS SQUIBB</td>
<td>C3</td>
</tr>
<tr>
<td>CANON MEDICAL SYSTEMS</td>
<td>N7</td>
</tr>
<tr>
<td>CELLTRION HEALTHCARE</td>
<td>B2</td>
</tr>
<tr>
<td>CESAS MEDICAL LIMITED</td>
<td>M11</td>
</tr>
<tr>
<td>CLARIUS MOBILE HEALTH</td>
<td>M4</td>
</tr>
<tr>
<td>CLINICAL AND EXPERIMENTAL RHEUMATOLOGY</td>
<td>M5</td>
</tr>
<tr>
<td>CSL VIFOR</td>
<td>D1</td>
</tr>
<tr>
<td>DS MEDICA</td>
<td>N4</td>
</tr>
<tr>
<td>ELI LILLY</td>
<td>L1/L2</td>
</tr>
<tr>
<td>ESAOTE</td>
<td>N9</td>
</tr>
<tr>
<td>EXPANSCIENCE</td>
<td>N2.2</td>
</tr>
<tr>
<td>FIDIA FARMACEUTICI</td>
<td>A3.1</td>
</tr>
<tr>
<td>FRESENIUS KABI</td>
<td>A3.2/B3</td>
</tr>
<tr>
<td>GALAPAGOS</td>
<td>E1/E2</td>
</tr>
<tr>
<td>GE HEALTHCARE</td>
<td>N3/N8</td>
</tr>
<tr>
<td>GSK</td>
<td>C1/C2</td>
</tr>
<tr>
<td>HORIZON THERAPEUTICS</td>
<td>A4</td>
</tr>
<tr>
<td>IBSA INSTITUTE BIOCHIMIQUE</td>
<td>N2.1</td>
</tr>
<tr>
<td>JANSSEN</td>
<td>H1/I1</td>
</tr>
<tr>
<td>MEDAC</td>
<td>C4</td>
</tr>
<tr>
<td>MERCK</td>
<td>M8/M9</td>
</tr>
<tr>
<td>NORDIC PHARMA</td>
<td>B1.2</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>H2/H3+I2/I3</td>
</tr>
<tr>
<td>OTSUKA</td>
<td>N1.1</td>
</tr>
<tr>
<td>PERIMED</td>
<td>N11</td>
</tr>
<tr>
<td>PFIZER</td>
<td>L3/L4</td>
</tr>
<tr>
<td>PHILIPS</td>
<td>N6</td>
</tr>
<tr>
<td>PRIOVANT THERAPEUTICS</td>
<td>M12</td>
</tr>
<tr>
<td>ROCHE</td>
<td>D2</td>
</tr>
<tr>
<td>ROPCA</td>
<td>M6</td>
</tr>
<tr>
<td>THE JOURNAL OF RHEUMATOLOGY</td>
<td>N10</td>
</tr>
<tr>
<td>UCB</td>
<td>M1/M2</td>
</tr>
<tr>
<td>XIRALITE</td>
<td>M7</td>
</tr>
</tbody>
</table>
THE HOSPITALITY SUITES  HALL 4, LEVEL 2

<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBVIE</td>
<td>E3/F3</td>
</tr>
<tr>
<td>AMGEN</td>
<td>B3</td>
</tr>
<tr>
<td>BOEHRINGER INGELHEIM</td>
<td>D3</td>
</tr>
<tr>
<td>BRISTOL MYERS SQUIBB</td>
<td>B2</td>
</tr>
<tr>
<td>CSL VIFOR</td>
<td>D4.2</td>
</tr>
<tr>
<td>ELI LILLY</td>
<td>D2</td>
</tr>
<tr>
<td>GALAPAGOS</td>
<td>E2</td>
</tr>
<tr>
<td>JANSSEN</td>
<td>C3.2</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>B1</td>
</tr>
<tr>
<td>PFIZER</td>
<td>F1</td>
</tr>
<tr>
<td>UCB</td>
<td>F2</td>
</tr>
</tbody>
</table>

THE HOSPITALITY MEETING ROOMS  HALL 4, LEVEL 2

<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGEN</td>
<td>MR C4.1</td>
</tr>
<tr>
<td>ASTRAZENECA</td>
<td>MR E4.1/G3/G4</td>
</tr>
<tr>
<td>FOREUM</td>
<td>MR E4.2</td>
</tr>
<tr>
<td>GSK</td>
<td>MR A4</td>
</tr>
<tr>
<td>HORIZON THERAPEUTICS</td>
<td>MR A2</td>
</tr>
<tr>
<td>IDORSIA PHARMACEUTICALS</td>
<td>MR G2</td>
</tr>
<tr>
<td>JANSSEN</td>
<td>MR G6</td>
</tr>
<tr>
<td>MERCK</td>
<td>MR A3</td>
</tr>
<tr>
<td>NOVARTIS</td>
<td>MR A1</td>
</tr>
<tr>
<td>PRIOVANT THERAPEUTICS</td>
<td>MR B5.2</td>
</tr>
<tr>
<td>REMEGEN BIOSCIENCES</td>
<td>MR G1</td>
</tr>
<tr>
<td>ROCHE</td>
<td>MR G5</td>
</tr>
<tr>
<td>SANOFI</td>
<td>MR B5.1</td>
</tr>
<tr>
<td>TREND COMMUNITY</td>
<td>MR C4.2</td>
</tr>
</tbody>
</table>

THE HOSPITALITY LOUNGES  HALL 3, LEVEL 1

<table>
<thead>
<tr>
<th>Company</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMGEN</td>
<td>BALCONY LOUNGE 6</td>
</tr>
<tr>
<td>GALAPAGOS</td>
<td>BALCONY LOUNGE 4</td>
</tr>
<tr>
<td>PROMETHEUS BIOSCIENCES</td>
<td>BALCONY LOUNGE 5</td>
</tr>
</tbody>
</table>
**ABBVIE**

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit our website.

AbbVie  
1 North Waukegan Road,  
North Chicago, IL 60064  
United States  
www.abbvie.com
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website.
UCB

UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology now and into the future. We work with stakeholders to address the unmet needs of patients and caregivers, helping them achieve their goals and live the lives they want. UCB is on a journey to become the biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.

At EULAR 2023, UCB is the proud sponsor of two sessions which include:
· “The Time is NOW! Aiming for Higher Treatment Targets in PsA and axSpA” – Satellite Symposium
· “Facing the Challenges of the Impact of Gender in SpA” – Consult the Expert session

© UCB Biopharma SRL, 2023. All rights reserved.
IT-N-DA-RH-2300029 Date of preparation: April 2023
Intended for healthcare professionals
At Janssen Immunology, it is our mission to redefine immune disease treatments through transformational and accessible therapies and regimens.

The Immunology Therapeutic Area of Janssen Research & Development LLC has over 20 years experience in therapies for autoimmune and inflammatory disease, including: the discovery, development, and commercialization of monoclonal antibodies; offering the first anti-tumor necrosis factor antibody; and demonstrating the roles of inhibiting IL-12 and IL-23 in immune-mediated inflammatory disease.

Today, our remain portfolio has expanded to include novel, oral small molecules and new biologic platforms (these are both at investigational stage), and we continue to expand our research into challenging areas of high unmet medical need.

Our work is based on deep scientific understanding of the diseases we treat, helping drive discovery. Our scientists in research and clinical development collaborate with medical affairs, market access and commercial teams to enable learnings, that run from bench to bedside; with the common goal of advancing science to improve patients’ lives.

We look to a leader in optimizing and tailoring therapeutic advances, to target the right treatment for the right person in every part of the world.

Janssen Pharmaceutica NV
Turnhoutseweg 30
2340 Beerse, Belgium
www.janssen.com/emea
Eli Lilly and Company

Eli Lilly and Company
Indianapolis, IN 46285
USA
www.lilly.com
Novartis is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 106,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world. Find out more by visiting our website.

Novartis Pharma AG
Basel
CH-4002
Switzerland
www.novartis.com
BOEHRINGER INGELHEIM

BOEHRINGER INGELHEIM INFLAMMATION:
PIONEERING SCIENCE, INSPIRED BY PATIENTS

INSPIRED BY PATIENTS
Living with inflammatory and fibrotic diseases greatly impacts patients’ lives, both physically and emotionally. Many patients are facing these challenges with limited treatment options. These patients guide and inspire us to turn innovative science into life-changing medical breakthroughs.

OUR COMMITMENT IS UNBREAKABLE
As a family-owned company, we make long-term plans and commitments to patients and the healthcare community. We work every day with passion and integrity, advancing treatments in the most hard-to-treat inflammatory and fibrotic diseases of the lung, gut, skin and joints.

PIONEERING SCIENCE TO DELIVER BREAKTHROUGH TREATMENTS
Our goal is to rapidly discover and develop breakthrough therapies that change lives. Through a deep understanding of molecular pathways linked to biomarkers of disease, we pioneer innovations that can be used to prevent, treat and repair many inflammatory and fibrotic diseases. With our precision-medicine approach, we seek to tailor the right treatment to the right patient, at the right time.

PARTNERING TO DELIVER VALUE TO PATIENTS
We work together through long-term partnerships to deliver ground-breaking innovation, optimizing the use of data, digital and device technologies to accelerate value creation for patients. We are committed to pursuing access worldwide and removing barriers for patients who could benefit from our innovations.

WE WON’T REST UNTIL WE CAN GIVE PEOPLE THE CHANCE TO LIVE THE LIFE THEY WANT.
MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH

medac is a privately held pharmaceutical company with a growing pharmaceutical and diagnostics business. Medicinal products from medac support doctors and patients throughout the world in overcoming acute and chronic diseases in the indication areas of oncology, haematology, urology and autoimmune disorders. In addition, medac develops and markets special diagnostic test systems.

Since 1970 medac has been committed to unifying therapeutic and diagnostic areas under one roof.

medac GmbH
Theaterstraße 6
22880 Wedel
Germany
www.medac.de

BRISTOL MYERS SQUIBB

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

Bristol Myers Squibb
3401 Princeton Pike
Lawrence Township, NJ
USA 08648
www.bms.com
We are united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life.

We are a fully integrated biotechnology company focused on discovering, developing and commercializing innovative medicines in areas of high unmet need.

Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies.

We have a forward-thinking approach to science and how we interact with people living with immune-mediated diseases. Patients are at the heart of everything we do, and meeting their unmet needs in immunology is the driving force behind our work.

We have forged a 10-year transformative research and development agreement with Gilead, advancing research efforts across all focus areas in immunology...

Through our deep experience in innovation and immunology, we are relentless in our pursuit of new solutions to overcome the medical challenge of immune-mediated diseases. This led to our discovery of the JAK1 signaling pathway in rheumatoid arthritis (RA) and the development of a JAK1 preferential inhibitor, which was granted marketing authorization in Europe and Japan for the treatment of RA in 2020 and UC in 2021/2022.

Scientific innovation is at our core as we continue to find better ways to manage immune-mediated diseases such as RA, inflammatory bowel disease (BD), systemic lupus erythematosus (SLE) and beyond.

Galapagos NV
Generaal De Wittelaan L11 A3
2800 Mechelen
Belgium
www.glpg.com
AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

GSK PLC

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology. We are working to unlock the science of the immune system to improve outcomes for people affected by immune-mediated conditions. We will be sharing and discussing the latest science and emerging evidence around immune-mediated conditions at EULAR 2023. Please visit us at our booth, attend our industry symposia and consult the expert educational sessions to learn more about GSK in immunology.

©2023 GSK group of companies. All rights reserved.
NP-GBL-BEL-WCNT-230009
Date of preparation: April 2023
AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. We are committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with inhaled and biologic medicines today as well as new modalities for the future to address previously unreachable biologic targets. Our ambition is to transform care in respiratory & immune-mediated diseases by moving beyond symptom control to achieve disease modification, remission and, one day, cures for millions of people worldwide. By delivering life-changing medicines and catalysing transformations in care we aim to eliminate COPD as a leading cause of death, eliminate asthma attacks, achieve clinical remission in asthma and transform other respiratory diseases with limited or no treatment options. In immune-mediated disease we aim to deliver clinical remission for the majority of patients and bring much needed treatment options to disease areas with a huge unmet need.
ROCHE

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

For more information, please visit our website.

F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
4070 Basel
Switzerland
www.roche.com
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used for the therapy and care of critically and chronically ill patients.

Its product portfolio comprises a range of highly complex biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs. Within biopharmaceuticals, Fresenius Kabi offers, among others, biosimilar drugs with a focus on autoimmune diseases and oncology. The company’s clinical nutrition offering includes a wide selection of enteral and parenteral nutrition products. In the segment of medical technologies, its offering includes vital disposables, infusions pumps, apheresis machines, cell therapy devices, and more.

With its corporate mission of “caring for life”, Fresenius Kabi puts essential medicines and technologies in the hands of people who help patients and finds the best answers to the challenges they face.

Following its “Vision 2026”, the company is furthermore committed to increase efficiencies in the therapy and care of patients and improve access to high-quality healthcare around the globe. Fresenius Kabi aspires to be leading globally in its product segments – all for the benefit of patients, its customers, and its stakeholders.

For more information, please visit our website.
IBSA

IBSA Institut Biochimique SA is a pharmaceutical company headquartered in Lugano, Switzerland, and active in 10 main therapeutic areas (OA, Pain, Dermatology, Cardiometabolic, Dermaoesthetic, Endocrinology, Human Reproduction, Respiratory, Urology, Integrative care). IBSA's portfolio for OA and musculoskeletal pathologies includes different therapeutic options: i.e. oral pharmaceutical-grade chondroitin sulfate, a wide range of highly purified biofermentative hyaluronic acids for intra-articular use, topical forms of diclofenac epolamine, a new low-dosage diclofenac as oral softgels and vitamin D3 as orodispersible film (ODF).

IBSA Institut Biochimique SA
Via Pian Scairolo 49
6912 Lugano-Pazzallo
Switzerland
www.ibsagroup.com

CELLTRION HEALTHCARE CO., LTD.

Celltrion Healthcare conducts worldwide marketing, sales and distribution of biological medicines developed by Celltrion Inc. Celltrion Healthcare is committed to delivering innovative and affordable medications to promote patients' access to advanced therapies.

Celltrion Healthcare endeavours to offer high-quality cost-effective solutions through an extensive global network that spans more than 110 different countries.

Celltrion Healthcare Co., Ltd
19, Academy-ro 51beon-gil
Yeosu-gu,
Incheon, 22014
Korea
www.celltrionhealthcare.com
CSL VIFOR

CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries.

CSL Vifor
Rechenstrasse 37
9014 St. Gallen
Switzerland
www.CSLVifor.com

MERCK KGAA

Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company’s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine) tablets. Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

MERCK KGAA
Headquarters of the Merck Group
Frankfurter Strasse 250
Darmstadt, 64293,
Germany
Phone: +496151720
Fax: +496151722000
www.merckgroup.com
service@merckgroup.com
OTSUKA PHARMACEUTICAL

Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: “Otsuka-people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative products, focusing on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging area of mental health and also has research programs in several under-addressed diseases including tuberculosis, a significant global public health issue.

Otsuka employs around 550 people in Europe and focuses on psychiatric and neurologic disorders, infectious disease, nephrology, oncology, and digital medicines. Otsuka Italy is an affiliate of Otsuka Pharmaceutical Europe Ltd. which is a part of Otsuka Pharmaceutical Company, Ltd., a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan.

The Otsuka group of companies employed 47,000 people worldwide with consolidated sales of approximately €12.4 billion and a spend of €1.67 billion on research and development in 2022.

For further information on Otsuka in Europe, please visit our website.

Otsuka Pharmaceutical Italy S.r.l.
Via Fabio Filzi 29
20124 Milan
Italy
www.otsuka-europe.com
**ACCORD HEALTHCARE**

Accord Healthcare is a fast-growing global pharmaceutical company that develops, manufactures and distributes generic, biosimilar and added-value medicines in over 85 countries worldwide, helping to improve access for patients to vital pharmaceutical care at the point of need. By challenging the status quo and directly addressing unmet clinical and societal needs, Accord continuously strives to make things better by delivering high quality medicines to patients, faster, more economically, reliably and with greater innovation than many other generic companies.

Accord’s portfolio spans across critical therapeutic fields such as oncology, cardiology, neurology, psychiatry, diabetes, pain management and gastroenterology.

Accord Healthcare EMENA HQ  
Sage House, 319 Pinner Road  
North Harrow, Middlesex  
HA1 4HF - London  
United Kingdom  
T: +44 (0) 208 863 1427  
F: +44 (0) 208 863 1427  
www.accord-healthcare.com

---

**ADAMO S.R.L**

Adamo S.r.l. comes from a multi-year experience in the field of video diagnostics in various specialized branches (reumatology, dermatology, trichoscopy, etc.).

During the years we have introduced new diagnostic methods for better visualization of static and dynamic morphological patterns and we foresee to continue to develop new technology, allowing a more accurate clinical diagnosis, also thanks to our constantly investment in research and development.

Another highlight is that our systems are the result of constant collaboration with all of our Customers: the continuous feedback with them is our starting point to make more performing hardware and software.

We take care of every details!!!

Adamo S.r.l.  
Via Francesco Culcasi n.1/B Z.I.R.  
Trapani (TP)  
Italy  
Tel.+39 0923 558778  
www.adamosrl.com  
info@adamosrl.com
APTISSEN

Founded in Switzerland in 2013, Aptissen is a leading-edge musculoskeletal expert that provides life-changing orthobiologic solutions for joint disorders.

Our founders developed a unique hyaluronic acid injectable, Synolis™, to reduce the pain and discomfort caused by osteoarthritis. In 2019, we added Cartylis™ to our portfolio. A daily drinkable food supplement, it promotes collagen synthesis to boost the joints.

The company’s products are distributed through a worldwide distributors network among more than 50 countries, including Switzerland, France, Italy, Poland, Germany, Canada, Mexico, Brazil, UAE, Singapore, Malaysia.

Aptissen SA
Chemin du Champ des Filles 36A
1228 Plan-les-Ouates
Switzerland
www.aptissen.com

BMJ

Annals of the Rheumatic Diseases (ARD) is a leading journal in the field of rheumatology, with an impact factor of 28.003 and a flagship in the rheumatology portfolio. This journal is an official journal of EULAR and provides a platform for groundbreaking research & innovative clinical practices. The journal is supported by RMD Open, an open access title focused on expanding knowledge on rheumatic and musculoskeletal diseases, with an impact factor of 5.806 and Lupus Science & Medicine, the first lupus-specific open access journal with an impact factor of 4.687. Our Rheumatology portfolio also includes the EULAR Textbook on Rheumatic Diseases, the EULAR Textbook on Paediatric Rheumatology, the EULAR Textbook on Systemic Sclerosis, and the EULAR Textbook on Musculoskeletal Ultrasound in Rheumatology, providing a comprehensive resource for rheumatologists and healthcare professionals.

BMJ
BMA House
Tavistock Square
London WC1H 9JR
United Kingdom
www.bmj.com
Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound and MRI, across the globe. As of December 2016, Canon Medical became a member of the Canon Group. In line with our continued Made For life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.

At Canon Medical we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life.
Clarius Mobile Health

High-Definition Wireless Ultrasound for Rheumatology

Clarius HD3 is the ideal wireless ultrasound scanner for high-resolution MSK imaging. Make a confident diagnosis and improve procedural safety with real-time imaging of joints, tendons, cartilage, and bone. Clear imaging helps to diagnose and differentiate inflammatory arthritis, even at early stages.

Image Clarity You Can Trust for a Confident Diagnosis

With 8 times the processing power of most handheld ultrasound systems, Clarius HD3 gives you high-resolution imaging of muscle and tissue to assess inflammatory changes and guide injections and aspirations with confidence. With AI assistance on your smart device, getting a great image is easy. Start scanning in seconds, then simply pinch to zoom, slide to change gain, and tap to switch modes.

- Confidently identify joint effusions
- Enhance diagnosis, expedite treatment, and improve clinical outcomes
- Evaluate and characterize rheumatoid nodules
- Guide articular and periarticular aspirations or injections
- Visualize subclinical changes such as synovitis, tenosynovitis, enthesitis, bone erosions, and crystal deposits
- Foster patient trust and commitment to your treatment plan

Clarius Mobile Health
9 Appold Street, 6th Floor
EC2A 2AP, London
United Kingdom
www.clarius.com
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY

Clinical and Experimental Rheumatology is a monthly international peer-reviewed journal which has been covering all clinical, experimental and translational aspects of musculoskeletal, arthritic and connective tissue diseases since 1983. This monthly journal also includes annual monothematic issues on the following topics: Behçet’s disease and other autoinflammatory conditions, Vasculitis, Scleroderma, Fibromyalgia and related syndromes, Sjögren’s syndrome, and Myositis.

CSF
Gothic Cottage
White Lion St
Stafford ST17 4BW
United Kingdom
www.cytokinesignalling.com/en/
https://lupus-forum.com/

CYTOKINE SIGNALLING FORUM

The CSF is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice.

The Lupus Forum is an educational website developed under the auspices of the University of Leeds and is dedicated to the dissemination of the latest developments in the field of lupus. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of lupus, its treatments, and clinical practice.

Clinical and Experimental Rheumatology
via Santa Maria 31,
56126 Pisa,
Italy
www.clinexprheumatol.org
**DS MEDICA**

DS Medica is the leader company in Italy in diagnostic imaging and clinical nutrition.

Since 1979 DS Medica has contributed to the development of innovative diagnostic and therapeutic technologies in different medicine fields; since 1986 Videocap® is an established and successful brand in dermatology and rheumatology!

Videocap® is the DS Medica product line dedicated to epiluminescence, immersion and polarized light video biomicroscopes, which satisfy the multiple and different needs of differential diagnostics.

DS Medica srl  
Via Teodosio 74  
20131 – Milan, Italy  
www.dsmedica.info

---

**ESAOTE**

Esaote is one of the world’s leading producers of medical diagnostic systems with a unique value proposition, providing medical imaging solutions in Ultrasound and Dedicated MRI.

It offers an extended range of products specifically tuned to rheumatology applications and able to satisfy any clinical need.

The ultrasound MyLab family boasts a complete range of Rheuma-dedicated systems, from portable to premium-end products. Be sure to stop by Esaote Booth N9 (HALL 3).

Esaote S.p.A.  
Via E. Melen, 77  
16152 Genoa – Italy  
www.esaote.com
EUSA PHARMA

We are committed to transforming the lives of people affected by cancer or rare disease, globally. We continuously strive to uncover opportunities which address gaps across adult and paediatric care. Helping the people with few or no options available is at the heart of everything we do.

EUSA Pharma is part of Recordati Rare Diseases, the business unit dedicated to rare disease in the Recordati group. Recordati has a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals.

We see a need. We work together. We don’t give up.

EUSA Pharma UK Ltd
Breakspear Park,
Breakspear Way,
Hemel Hempstead HP2 4TZ,
United Kingdom
www.eusapharma.com

LABORATOIRES EXPANSIENCE

We are convinced that aging and quality of life can be reconciled. This is why we help millions of individuals who suffer from osteoarthritis to continue doing what they love for as long as possible, by incarnating health that is committed to serving the greatest number. We design therapeutic solutions, we develop services that help patients take charge of their illness, and we are mobilized along with healthcare professionals and the society as a whole to improve prevention, diagnosis and compliance.

Laboratoires Expanscience
1 place des saisons
92048 Paris La Défense Cedex
France
www.expanscience.com/en
FIDIA FARMACEUTICI

Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based on natural and functionalized hyaluronic acid (+1,100 patents), in joint care, wound care, ophthalmology, uro-gynecology, aesthetic and regenerative medicine. Manufacturing operations, located in Italy, are inspected and approved by major international health authorities, including the US FDA, and the company extends its global reach through wholly owned subsidiaries and commercial partners in +100 countries worldwide.

Fidia Farmaceutici S.p.A.
Via Ponte della Fabbrica 3/A
35031 Abano Terme (PD)
Italy
www.fidiapharma.it

GE HEALTHCARE

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services and data analytics to make clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing connected and compassionate care, while simplifying the patient’s journey across the care pathway. Together, we’re creating a world where healthcare has no limits. Learn more by visiting our website.

GE HealthCare
Beethovenstrasse 239
42665 Solingen
Germany
www.gehealthcare.com
HORIZON THERAPEUTICS

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.

Horizon Therapeutics
1 Horizon Way
Deerfield, IL 60015
www.horizontherapeutics.com

IDORSIA

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients.

We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options.

In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.

Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland
www.idorsia.com
**KYVERNA**

Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna’s pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases.

**MEDSCAPE**

Medscape is the leading online global destination for physicians and healthcare professionals worldwide, offering the latest medical news and expert perspectives; essential point-of-care drug and disease information; and relevant professional education and CME.
NORDIC PHARMA

Nordic Pharma is a privately owned, medium-size Pharma company with a history of internal product development and acquisitions.

We hold an established position in Women’s Health, a fast-growing Rheumatology franchise with a global footprint, and an increasing presence in Critical Care and Ophthalmology.

Making a sustainable impact on people’s health. With the aim of being patient focused and providing rheumatoid arthritis patients with devices adapted to their disease, Nordic Pharma conceived and developed its solution for injectable Methotrexate.

NORDiMET® Auto-injector and NORDiMET® in prefilled-syringes are indicated in active Rheumatoid Arthritis in adults, among other indications in rheumatology, gastroenterology and dermatology.

Nordic Pharma strives to bring innovative and efficient solutions to unmet medical needs, contributing to improved patient care.

Nordic Pharma
216, bd Saint-Germain
75007 Paris
www.nordicpharmagroup.com
PERIMED

Perimed is a private Swedish company active on the global market, with seven subsidiaries and more than twenty distributors around the world. We have more than 40 years of experience and unique competence in laser-based blood perfusion measurements, making Perimed a leader in peripheral vascular diagnosis. Our equipment is typically used in Wound Care Departments, Diabetic Foot Clinics, Vascular Surgery/Labs and Radiology. We have over 4300 installed instruments worldwide.

Perimed’s microcirculation imager, the PeriCam PSI, has been shown to be a reliable tool for measuring blood flow in systemic sclerosis (SSc) 1.


Perimed
Bizetstraat 11,
6661AX Elst,
Netherlands
www.perimed-instruments.com

PRIOVANT THERAPEUTICS

Priovant Therapeutics is a clinical-stage biotechnology company focused on delivering novel therapies for autoimmune diseases with the greatest morbidity and mortality. We are developing oral brepocitinib, a potential first-in-class dual inhibitor of TYK2 and JAK1, across multiple severe autoimmune indications, unlocking new treatment options for patients who are underserved by existing therapies.

Priovant Therapeutics
151 West 42nd Street
New York,
NY 10036
www.priovanttx.com
ROPCA APS

ROPCA drives automation for better patient care.

The ARTHritis Ultrasound Robot (ARTHUR) is the world’s first serf-service station where patients can collaborate with a robot to perform a complex diagnostic procedure without the presence of medically trained personnel.

ARTHUR is AI enabled and scans 22 joints on both hands autonomously. It also automates documentation after successful image acquisitions. It provides a disease assessment for Rheumatoid Arthritis. The generated report presents the results as a EULAR Omeract grade per joint to the clinician for decision support.

ARTHUR is fully CE certified as a medical device and currently in use in Denmark.

ROPCA ApS
Campusvej 55
5230 Odense M
Denmark
www.ropca.com
SWEDISH ORPHAN BIOVITRUM AB

Within the therapeutic area of Immunology, Sobi is dedicated to the treatment of rare, ultra-rare and severe diseases. This dedication combined with a rare expertise has resulted in a long history of developing transformative treatments for patients with high unmet medical needs. Our ability to identify unmet medical needs, develop treatments and secure evidence has been instrumental in the success of our current therapies. Our track record in getting innovative treatments to the people who need them positions us well to take a leading role in Immunology. We keep challenging the status quo and are dedicated to the continuous discovery of high-potential therapies that we can develop to make a lasting impact and create sustainable value, sooner rather than later. Through close collaboration with rare disease communities, we continue to improve access to care for those otherwise overlooked.

Swedish Orphan Biovitrum AB
SE-112 76 Stockholm
Sweden
info@sobi.com
www.sobi.com
THE JOURNAL OF RHEUMATOLOGY

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring peer-reviewed research articles on clinical subjects from scientists working in rheumatology and related fields, with the support of our esteemed Editorial Committee and Editorial Board. With over 1600 submissions a year from over 50 countries, each issue of The Journal of Rheumatology includes original clinical research articles, metanalyses, editorials, historical vignettes, case reports, and letters by world-renowned experts studying drug therapy, patient-reported outcomes, discovery of therapeutic targets in the treatment of rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, osteoarthritis, and other rheumatic and musculoskeletal diseases.

WISEPRESS

Wisepress.com, Europe’s leading conference bookseller, attend around 200 conferences every year. We have an extensive range of books and journals relevant to the themes of this conference available at our booth. We also have a comprehensive range of STM titles available on our online bookshop. Follow us on Twitter @WisepressBooks.
XIRALITE GMBH

Xiralite GmbH is a medical device company located in the heart of Berlin, Germany. We offer innovative concepts for the diagnosis and therapy of several diseases, thereby providing significantly improved benefits to our customers. Xiralite’s key technology is based on fluorescence optical imaging and our medical imaging devices enable diagnostics of microcirculation disorders. Through this unique technology, alterations of the microcirculation become visible allowing for the identification of different types of rheumatic diseases. Our devices are installed worldwide in clinical practices, hospitals and research institutions.

Xiralite GmbH
Luisencarrée
Robert-Koch-Platz 4
10115 Berlin
Germany
Phone: +49 (0)30.890 49 74 - 31
www.xiralite.com